Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amiodarone for prevention of new-onset atrial fibrillation after TAVI
2018-004202-25Phase 3Active
- Sponsor
- Luis Nombela Franco
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Amiodarone with Placebo (2 arms). Primary endpoint: Incidence of new-onset atrial fibrillation within 30 days after TAVI. Started Jun 2019; status: active.
02
Drugs
amiodarone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2018-004202-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004202-25.